Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells

Hemant Sarin, Ariel S. Kanevsky, Haitao Wu, Kyle R. Brimacombe, Steve H. Fung, Alioscka A. Sousa, Sungyoung Auh, Colin M. Wilson, Kamal Sharma, Maria A. Aronova, Richard D. Leapman, Gary L. Griffiths, Matthew D. Hall

Research output: Contribution to journalArticlepeer-review

202 Scopus citations


Background: Effective transvascular delivery of nanoparticle-based chemotherapeutics across the blood-brain tumor barrier of malignant gliomas remains a challenge. This is due to our limited understanding of nanoparticle properties in relation to the physiologic size of pores within the blood-brain tumor barrier. Polyamidoamine dendrimers are particularly small multigenerational nanoparticles with uniform sizes within each generation. Dendrimer sizes increase by only 1 to 2 nm with each successive generation. Using functionalized polyamidoamine dendrimer generations 1 through 8, we investigated how nanoparticle size influences particle accumulation within malignant glioma cells. Methods: Magnetic resonance and fluorescence imaging probes were conjugated to the dendrimer terminal amines. Functionalized dendrimers were administered intravenously to rodents with orthotopically grown malignant gliomas. Transvascular transport and accumulation of the nanoparticles in brain tumor tissue was measured in vivo with dynamic contrast-enhanced magnetic resonance imaging. Localization of the nanoparticles within glioma cells was confirmed ex vivo with fluorescence imaging. Results: We found that the intravenously administered functionalized dendrimers less than approximately 11.7 to 11.9 nm in diameter were able to traverse pores of the blood-brain tumor barrier of RG-2 malignant gliomas, while larger ones could not. Of the permeable functionalized dendrimer generations, those that possessed long blood half-lives could accumulate within glioma cells. Conclusion: The therapeutically relevant upper limit of blood-brain tumor barrier pore size is approximately 11.7 to 11.9 nm. Therefore, effective transvascular drug delivery into malignant glioma cells can be accomplished by using nanoparticles that are smaller than 11.7 to 11.9 nm in diameter and possess long blood half-lives.

Original languageEnglish (US)
Article number80
JournalJournal of Translational Medicine
StatePublished - Dec 18 2008

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells'. Together they form a unique fingerprint.

Cite this